The purpose of this study is to assess whether TNFa antibody use before lung transplant can prevent kidney injury after lung transplant.
After being informed about the study and potential risks, all patients giving written consent who undergo a lung transplant will be randomized in a 1:1 ratio to either the treatment or control group. Patients randomized to the treatment group will receive one dose of the study drug, Etanercept, via subcutaneous injection just prior to the lung transplant. Patients randomized to the control group will not receive Etanercept. Both groups will receive standard lung transplant care after implantation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
20
25 mg subcutaneous injection
Northwestern University
Chicago, Illinois, United States
Occurrence of kidney dysfunction immediately after lung transplant
Measured by serum creatinine blood tests
Time frame: Immediately after lung transplant
Occurrence of kidney dysfunction post-operatively within 1 week after lung transplant
Measured by serum creatinine blood tests
Time frame: Within 1-7 days after lung transplant
Occurrence of kidney dysfunction post-operatively within 1 month after lung transplant
Measured by serum creatinine blood tests
Time frame: Up to 30 days after lung transplant
Occurrence of primary graft dysfunction
Measured by arterial blood gas (ABG) blood tests and chest X-rays
Time frame: Within 3 days post-transplant
Length of intensive care unit (ICU) stay
Measured by number of days in the ICU post-transplant
Time frame: Through study completion, an average of 1 year
Length of ventilator use
Measured by number of days on a ventilator post-transplant
Time frame: Through study completion, an average of 1 year
Survival
Alive or dead post-transplant
Time frame: 30 days, 90 days, and one year survival post-transplant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.